Longevity Startups

Jyzen offers personalized integrative medicine and wellness programs focused on healthy aging, longevity, chronic disease resolution, cognitive function, and performance optimization. It combines medical providers with fitness and wellness practitioners, using a diagnostics, detox, optimization, and maintenance process to deliver individualized care.

0 investors

Khloris Biosciences develops iPSC-based cancer vaccines, using induced pluripotent stem cells to trigger a multi-faceted anti-tumor immune response. The company focuses on identifying novel targets and vaccine candidates for cancer treatment.

0 investors

Klothea develops mRNA-based therapeutics designed to trigger adjustable and reversible secretion of the Klotho protein, aiming to address the protein deficit linked to age-related diseases. The company uses proprietary mRNA and safe nanocarriers intended for repeated use, and is also evaluating delivery methods such as extracellular vesicles (exosomes).

0 investors

Koyo Sciences is a biotechnology company developing an oral human growth hormone therapy derived from algae as a non-invasive alternative to injectable treatments for Growth Hormone Deficiency. Its research spans biology, chemistry, and data with a focus on health and sustainability.

0 investors

LifeCyte develops oral combination therapies that target chronic inflammation at the cellular level to slow the progression of age-related degenerative diseases such as macular degeneration, mild cognitive impairment, Alzheimer's, and traumatic brain injury. Its lead prototype, RestoViz, is aimed at age-related macular degeneration in older adults.

0 investors

Longevity Medical Institute provides regenerative medicine, anti-aging therapies, and diagnostics for patients seeking personalized care. The clinic combines stem cell therapy, hormone optimization, aesthetic medicine, and advanced diagnostics with specialists across multiple disciplines to address age-related health conditions.

0 investors

MD Hyperbaric operates medically-supervised hyperbaric oxygen therapy (HBOT) centers nationwide, treating conditions including chronic wounds and neurological injuries by delivering oxygen in pressurized environments. The company serves patients seeking non-invasive therapeutic treatment for healing and recovery.

0 investors

A clinical-stage biotech company developing novel drugs based on isotope-selective modulation technology, with patented drug compositions and a proprietary development platform currently in clinical trials.

0 investors

Mitochon is an early-stage biopharmaceutical company developing therapeutics. The page does not provide details about specific products, target indications, or customer segments beyond the biopharmaceutical sector.

0 investors

MitoSense develops Mitochondria Organelle Transplantation (MOT) technology, a cellular biotherapy that uses mitochondria to treat neurodegenerative diseases such as ALS, Parkinson's, and Alzheimer's. The company holds an exclusive license to the MOT technology and is developing it as a cell therapy.

0 investors

Morphoceuticals is a TechBio company mapping the "bioelectrome" — the body's cellular communication networks that govern tissue repair and organ regeneration. It combines multi-omics, bioelectric profiling, and AI to modulate ion channels for applications in regenerative medicine.

0 investors

Myosana Therapeutics develops non-viral, muscle-targeted gene therapies aimed at slowing skeletal muscle degeneration and heart failure in Duchenne muscular dystrophy (DMD) and other neuromuscular and cardiac diseases. The company works in the biotech and gene therapy field.

0 investors

Myris Therapeutics applies polymer chemistry to develop next-generation medicines, with a flagship platform of ultra-high DAR antibody drug conjugates (ADCs). Its technology uses ATRP "growing from" methods to build polymer bottlebrushes that carry payloads, aimed at targeted cancer therapies across oncogenic pathways.

0 investors

Natsar Pharmaceuticals is an applied research and drug development company developing RK-33, a first-in-class small molecule inhibitor of the DDX3 RNA helicase for treating cancers such as lung, breast, prostate, sarcoma, and pancreatic tumors, as well as viral infections including SARS-CoV-2 and HIV. The company is preparing to file an IND and move RK-33 into Phase 1 clinical trials.

0 investors

NeuroInitiative is a computational biology company that uses a patented AI simulation platform to model neural molecular interactions and prioritize drug targets across aging biology and neurodegeneration. Its platform produced Vincere Biosciences' VB-23, a USP30 inhibitor Parkinson's disease therapy entering Phase 1 clinical trials in 2026.

0 investors

Oragenics develops treatments for concussion and traumatic brain injury, focusing on clinical development of therapeutic candidates. The company combines neuroscience expertise with healthcare operational leadership to advance solutions for brain injury treatment.

0 investors

Personalized Stem Cells develops regenerative medicine treatments using stem cells derived from adipose tissue, serving patients seeking cell therapies for conditions like osteoarthritis and other ailments in both humans and animals. The company operates from San Diego under FDA guidelines and offers stem cell banking and treatment services through its StemReady and StemPreserve programs.

0 investors

Prolifagen develops microRNA (miR) technology to stimulate the regeneration of heart muscle damaged by myocardial infarction, aiming to prevent scar tissue formation and restore cardiac function. The company targets physicians and heart attack patients seeking solutions to prevent heart failure and recurrent cardiac events.

0 investors

ProtoKinetix develops a proprietary anti-aging glycopeptide (AAGP®) designed to improve cell survival and viability, with applications across ophthalmology, dermatology, transplantation, and biomanufacturing. The company conducts research and clinical studies focused on cryopreservation and cell replacement therapies for chronic conditions.

0 investors

Renue Life Sciences develops next-generation therapies for age-related and complex diseases, working in areas such as cell and gene therapy, RNA therapeutics, and CRISPR-based approaches. The company targets researchers, partners, and investors in the biotech and longevity space.

0 investors

Retain Health builds software that guides individuals to adopt brain-healthy habits through personalized, evidence-based recommendations aimed at reducing the risk of Alzheimer's disease. Its non-invasive tools focus on behavior change and prevention education, designed to scale across broad populations.

0 investors

Revalesio is a clinical-stage pharmaceutical company developing mitochondrial-targeted therapies for stroke and neurodegenerative diseases. The company focuses on treatments that restore mitochondrial health to improve cellular recovery and protect neurons in acute brain injury and aging-related neurological decline.

0 investors

Rezilir Health is a precision medicine clinic offering brain health, longevity, and complex chronic condition care, including therapies such as hyperbaric oxygen, IV infusions, ketamine, neurofeedback, and genetic testing. It serves patients with neurodegenerative disease, autoimmune disorders, dementia, and environmental illnesses from its Hollywood, Florida location.

0 investors

S1P Therapeutics is a preclinical-stage biotechnology company developing drugs that target novel nodes in the S1P pathway for treating kidney and autoimmune diseases. Its aim is to create medicines with less toxicity than existing S1P pathway drugs.

0 investors